<![CDATA[Bitopertin Meets All End Points in Phase 3 APOLLO Trial for EPP]]>

Дата публикации: 19-10-2026 13:07:35

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B	0	15.19	28-05-2026
2	PharmaEssentia Announces FDA Approval and U.S. Launch of BESREMi Pen™ (ropeginterferon alfa-2b-njft) for Polycythemia Vera	0	13.23	26-06-2026
3	Комбинированная терапия рака почки прошла третью фазу клинических испытаний	0	0	01-08-2025
4	Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes	0	22.68	12-06-2026
5	<![CDATA[GLP-1 Candidacy and Prescribing Considerations in Psoriasis]]>	0	10.41	19-10-2026
6	FDA Grants Traditional Approval to Retevmo (selpercatinib) for Locally Advanced or Metastatic RET Fusion-Positive Solid Tumors	0	8.58	14-07-2026
7	FDA Approves Lipfendra (enlicitide) Oral PCSK9 Inhibitor to Reduce LDL-C in Adults with Hypercholesterolemia	0	15.63	16-07-2026
8	Triple-action drug retatrutide delivers major weight loss for people with diabetes, Phase III trial finds	0	10.14	13-10-2026
9	Efficacy and Safety of Brolucizumab for Diabetic Macular Edema	0	7.97	01-12-2023

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 9. Тональность: 0. Информативность: 15.45. Источник: www.dermatologytimes.com.